American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 365-385 , February 2010

The Management of Diabetic Neuropathy in CKD

  • Rodica Pop-Busui, MD, PhD

      Affiliations

    • Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI
    • ,
  • Laurel Roberts, BS

      Affiliations

    • University of Michigan Medical School, Ann Arbor, MI
    • ,
  • Subramaniam Pennathur, MD

      Affiliations

    • Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI
    • ,
  • Mathias Kretzler, MD

      Affiliations

    • Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI
    • ,
  • Frank C. Brosius, MD

      Affiliations

    • Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI
    • ,
  • Eva L. Feldman, MD, PhD

      Affiliations

    • Department of Neurology, University of Michigan, Ann Arbor, MI
    • Corresponding Author InformationAddress correspondence to Eva L. Feldman, MD, PhD, Russell N. DeJong Professor of Neurology, University of Michigan Department of Neurology, 5017 BSRB, 109 Zina Pitcher Pl, Ann Arbor, MI 48109-2200

Received 7 August 2009 ,Accepted 29 October 2009.

References 

  1. Kamal-Bahl SJ, Pantely S, Pyenson B. Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease [abstract]. Prev Chronic Dis. 2006;3(3):83A;http://www.cdc.gov/pcd/issues/2006/jul/05_0210.htmAccessed September 1, 2009
  2. Fernando DJ, Hutchison A, Veves A, Gokal R, Boulton AJ. Risk factors for non-ischaemic foot ulceration in diabetic nephropathy. Diabet Med. 1991;8(3):223–225
  3. Navarro X, Kennedy WR, Sutherland DE. Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia. 1991;34(suppl 1):S108–S112
  4. Rathmann W, Ziegler D, Jahnke M, Haastert B, Gries FA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med. 1993;10(9):820–824
  5. Sampson MJ, Wilson S, Karagiannis P, Edmonds M, Watkins PJ. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q J Med. 1990;75(278):635–646
  6. Manjunath G, Levey AS, Sarnak MJ. How can the cardiac death rate be reduced in dialysis patients?. Semin Dial. 2002;15(1):18–20
  7. Locatelli F, Marcelli D, Conte F. Dialysis patient outcomes in Europe vs the USA (Why do Europeans live longer?). Nephrol Dial Transplant. 1997;12(9):1816–1819
  8. Locatelli F, Marcelli D, Conte F, et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol. 2001;12(11):2411–2417
  9. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;
  10. Ranpuria R, Hall M, Chan CT, Unruh M. Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrol Dial Transplant. 2008;23(2):444–449
  11. Hathaway DK, Cashion AK, Milstead EJ, et al. Autonomic dysregulation in patients awaiting kidney transplantation. Am J Kidney Dis. 1998;32(2):221–229
  12. Zander E, Schulz B, Heinke P, Grimmberger E, Zander G, Gottschling HD. Importance of cardiovascular autonomic dysfunction in IDDM subjects with diabetic nephropathy. Diabetes Care. 1989;12(4):259–264
  13. Chang MH, Chou KJ. The role of autonomic neuropathy in the genesis of intradialytic hypotension. Am J Nephrol. 2001;21(5):357–361
  14. Laaksonen S, Voipio-Pulkki L, Erkinjuntti M, Asola M, Falck B. Does dialysis therapy improve autonomic and peripheral nervous system abnormalities in chronic uraemia?. J Intern Med. 2000;248(1):21–26
  15. Spallone V, Mazzaferro S, Tomei E, et al. Autonomic neuropathy and secondary hyperparathyroidism in uraemia. Nephrol Dial Transplant. 1990;5(suppl 1):S128–S130
  16. Johansson M, Gao SA, Friberg P, et al. Reduced baroreflex effectiveness index in hypertensive patients with chronic renal failure. Am J Hypertens. 2005;18(7):995–1000discussion 1016
  17. Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg. 2004;107(1):1–16
  18. Innis J. Pain assessment and management for a dialysis patient with diabetic peripheral neuropathy. CANNT J. 2006;16(2):12–1720-16; quiz 18-19, 27-18
  19. Stella P, Ellis D, Maser RE, Orchard TJ. Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes (Incidence and predictors). J Diabetes Complications. 2000;14(1):1–6
  20. Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005;48(1):164–171
  21. Krishnan AV, Lin CS, Kiernan MC. Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain. 2008;131(pt 5):1209–1216
  22. Greene DA, Lattimer SA. Impaired energy utilization and Na-K-ATPase in diabetic peripheral nerve. Am J Physiol. 1984;246:E311–E318
  23. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008;120(1):1–34
  24. Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev. 2006;22(4):257–273
  25. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–82013
  26. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625
  27. Massry SG. Parathyroid hormone: a uremic toxin. Adv Exp Med Biol. 1987;223:1–17
  28. Slatopolsky E, Martin K, Hruska K. Parathyroid hormone metabolism and its potential as a uremic toxin. Am J Physiol. 1980;239(1):F1–F12
  29. Vanholder R, De Smet R, Hsu C, Vogeleere P, Ringoir S. Uremic toxicity: the middle molecule hypothesis revisited. Semin Nephrol. 1994;14(3):205–218
  30. Kaji R, Sumner AJ. Ouabain reverses conduction disturbances in single demyelinated nerve fibers. Neurology. 1989;39(10):1364–1368
  31. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC. Altered motor nerve excitability in end-stage kidney disease. Brain. 2005;128(pt 9):2164–2174
  32. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC. Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain. 2006;129(pt 6):1585–1592
  33. Craner MJ, Lo AC, Black JA, Waxman SG. Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain. 2003;126(pt 7):1552–1561
  34. Kiernan MC, Walters RJ, Andersen KV, Taube D, Murray NM, Bostock H. Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain. 2002;125(pt 6):1366–1378
  35. Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve. 2007;35(3):273–290
  36. Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912–1918
  37. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system?. J Hypertens. 2009;27(7):1341–1349
  38. Axelrod S, Lishner M, Oz O, Bernheim J, Ravid M. Spectral analysis of fluctuations in heart rate: an objective evaluation of autonomic nervous control in chronic renal failure. Nephron. 1987;45(3):202–206
  39. Campese VM, Romoff MS, Levitan D, Lane K, Massry SG. Mechanisms of autonomic nervous system dysfunction in uremia. Kidney Int. 1981;20(2):246–253
  40. Paulson DJ, Light KE. Elevation of serum and ventricular norepinephrine content in the diabetic rat. Res Commun Chem Pathol Pharmacol. 1981;33(3):559–562
  41. Givertz MM, Sawyer DB, Colucci WS. Antioxidants and myocardial contractility: illuminating the “dark side” of beta-adrenergic receptor activation?. Circulation. 2001;103(6):782–783
  42. Felten SY, Peterson RG, Shea PA, Besch HR, Felten DL. Effects of streptozotocin diabetes on the noradrenergic innervation of the rat heart: a longitudinal histofluorescence and neurochemical study. Brain Res Bull. 1982;8(6):593–607
  43. Scacco S, Vergari R, Scarpulla RC, et al. cAMP-dependent phosphorylation of the nuclear encoded 18-kDa (IP) subunit of respiratory complex I and activation of the complex in serum-starved mouse fibroblast cultures. J Biol Chem. 2000;275(23):17578–17582
  44. Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T, Sasayama S. Alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation. 1999;100(3):305–311
  45. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998;98(13):1329–1334
  46. Colberg SR, Swain DP, Vinik AI. Use of heart rate reserve and rating of perceived exertion to prescribe exercise intensity in diabetic autonomic neuropathy. Diabetes Care. 2003;26(4):986–990
  47. Giordano M, Manzella D, Paolisso G, Caliendo A, Varricchio M, Giordano C. Differences in heart rate variability parameters during the post-dialytic period in type II diabetic and non-diabetic ESRD patients. Nephrol Dial Transplant. 2001;16(3):566–573
  48. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med. 1980;49(193):95–108
  49. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J. 1982;285(6346):916–918
  50. Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care. 1986;9(6):648–665
  51. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387–397
  52. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy (The Consensus Committee of the American Autonomic Society and the American Academy of Neurology). Neurology. 1996;46(5):1470
  53. Kersh ES, Kronfield SJ, Unger A, Popper RW, Cantor S, Cohn K. Autonomic insufficiency in uremia as a cause of hemodialysis-induced hypotension. N Engl J Med. 1974;290(12):650–653
  54. Sato M, Horigome I, Chiba S, et al. Autonomic insufficiency as a factor contributing to dialysis-induced hypotension. Nephrol Dial Transplant. 2001;16(8):1657–1662
  55. Ligtenberg G, Blankestijn PJ, Boomsma F, Koomans HA. No change in automatic function tests during uncomplicated haemodialysis. Nephrol Dial Transplant. 1996;11(4):651–656
  56. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation. 1999;100(8):813–819
  57. Di Carli MF, Tobes MC, Mangner T, et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med. 1997;336(17):1208–1215
  58. Stevens MJ, Dayanikli F, Raffel DM, et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol. 1998;31(7):1575–1584
  59. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 1993;42(7):1017–1025
  60. Nitenberg A, Antony I, Foult JM. [Coronary vasoconstriction induced by acetylcholine in young smokers with normal angiographic coronary vessels]. Arch Mal Coeur Vaiss. 1993;86(8):1133–1136
  61. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol. 1995;25(3):610–618
  62. Schwartz PJ, Randall WC, Anderson EA, et al. Sudden cardiac death (Nonpharmacologic interventions). Circulation. 1987;76(1 pt 2):I215–I219
  63. Willich SN, Maclure M, Mittleman M, Arntz HR, Muller JE. Sudden cardiac death (Support for a role of triggering in causation). Circulation. 1993;87(5):1442–1450
  64. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med. 1976;294(21):1165–1170
  65. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003;26(6):1895–1901
  66. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J. 2000;140(6):848–856
  67. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;60(7):560–565
  68. Nishimura M, Hashimoto T, Kobayashi H, et al. Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients. Nephrol Dial Transplant. 2004;19(10):2532–2538
  69. Low PA, Denq JC, Opfer-Gehrking TL, Dyck PJ, O'Brien PC, Slezak JM. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle Nerve. 1997;20(12):1561–1568
  70. Gelber DA, Pfeifer M, Dawson B, Schumer M. Cardiovascular autonomic nervous system tests: determination of normative values and effect of confounding variables. J Auton Nerv Syst. 1997;62(1-2):40–44
  71. Heart rate variability: standards of measurement, physiological interpretation and clinical use (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology). Circulation. 1996;93(5):1043–1065
  72. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–962
  73. Allman KC, Wieland DM, Muzik O, Degrado TR, Wolfe ER, Schwaiger M. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol. 1993;22(2):368–375
  74. Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation. 1998;98(10):961–968
  75. Stevens MJ, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism. 1999;48(1):92–101
  76. Kreiner G, Wolzt M, Fasching P, et al. Myocardial m-[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM (Comparison with cardiovascular reflex tests and relationship to left ventricular function). Diabetes. 1995;44(5):543–549
  77. Schnell O, Kirsch CM, Stemplinger J, Haslbeck M, Standl E. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologia. 1995;38(11):1345–1352
  78. Schnell O, Muhr D, Weiss M, Dresel S, Haslbeck M, Standl E. Reduced myocardial 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes. 1996;45(6):801–805
  79. Shimabukuro M, Chibana T, Yoshida H, Nagamine F, Komiya I, Takasu N. Increased QT dispersion and cardiac adrenergic dysinnervation in diabetic patients with autonomic neuropathy. Am J Cardiol. 1996;78(9):1057–1059
  80. Turpeinen AK, Vanninen E, Kuikka JT, Uusitupa MI. Demonstration of regional sympathetic denervation of the heart in diabetes (Comparison between patients with NIDDM and IDDM). Diabetes Care. 1996;19(10):1083–1090
  81. Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol. 2004;44(12):2368–2374
  82. DeGrado TR, Hutchins GD, Toorongian SA, Wieland DM, Schwaiger M. Myocardial kinetics of carbon-11-meta-hydroxyephedrine: retention mechanisms and effects of norepinephrine. J Nucl Med. 1993;34(8):1287–1293
  83. Schwaiger M, Hutchins GD, Kalff V, et al. Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J Clin Invest. 1991;87(5):1681–1690
  84. Ungerer M, Hartmann F, Karoglan M, et al. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation. 1998;97(2):174–180
  85. Hamner JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. J Appl Physiol. 2001;91(3):1199–1206
  86. Foster AV, Snowden S, Grenfell A, Watkins PJ, Edmonds ME. Reduction of gangrene and amputations in diabetic renal transplant patients: the role of a special foot clinic. Diabet Med. 1995;12(7):632–635
  87. Eggers PW, Gohdes D, Pugh J. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int. 1999;56(4):1524–1533
  88. Combe C, Albert JM, Bragg-Gresham JL, et al. The burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2009;54(4):680–692
  89. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (American Diabetes Association). Muscle Nerve. 1988;11(7):661–667
  90. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27(6):1458–1486
  91. Adriaensen H, Plaghki L, Mathieu C, Joffroy A, Vissers K. Critical review of oral drug treatments for diabetic neuropathic pain-clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. Diabetes Metab Res Rev. 2005;21(3):231–240
  92. DCCT and UKPDS Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus (The Diabetes Control and Complications Trial Research Group). N Engl J Med. 1993;329:977–986
  93. DCCT and UKPDS Study Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol. 1995;38(6):869–880
  94. DCCT and UKPDS Study Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia. 1998;41(4):416–423
  95. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39(11):1377–1384
  96. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–350
  97. DCCT and UKPDS Study Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287(19):2563–2569
  98. DCCT/EDIC Writing Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA. 2003;290(16):2159–2167
  99. Pop-Busui R, Evans G, Gerstein HC, et al. Cardiac autonomic dysfunction predicts cardiovascular mortality in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes. 2009;(suppl 1):58:A63
  100. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117
  101. DCCT and UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (UK Prospective Diabetes Study (UKPDS) Group). Lancet. 1998;352(9131):837–853
  102. DCCT and UKPDS Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) (UK Prospective Diabetes Study (UKPDS) Group). Lancet. 1998;352(9131):854–865
  103. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
  104. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393
  105. Ondocin PT, Narsipur SS. Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis. Nephrology (Carlton). 2006;11(6):497–501
  106. Weinbergova O, Metelka R, Vymetal J, Konecny K, Kosatikova Z. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004;148(1):69–73
  107. Tamura K, Tsuji H, Nishiue T, Yajima I, Higashi T, Iwasaka T. Determinants of heart rate variability in chronic hemodialysis patients. Am J Kidney Dis. 1998;31(4):602–606
  108. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340(17):1321–1328
  109. Neumann J, Ligtenberg G, Klein IH, et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension. 2007;49(3):506–510
  110. Pun PH, Lehrich RW, Smith SR, Middleton JP. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol. 2007;2(3):491–500
  111. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–1444
  112. Nakao K, Makino H, Morita S, et al. Beta-blocker prescription and outcomes in hemodialysis patients from the Japan Dialysis Outcomes and Practice Patterns Study. Nephron Clin Pract. 2009;113(3):c132–c139
  113. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int. 2002;62(5):1784–1790
  114. Stojcheva-Taneva OO, Polenakovic MH. Autonomic neuropathy in hemodialysis patients treated with recombinant human erythropoietin. Int J Artif Organs. 1996;19(10):574–577
  115. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905–1913
  116. Ebbehoj E, Poulsen PL, Hansen KW, Knudsen ST, Molgaard H, Mogensen CE. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia. 2002;45(7):965–975
  117. Kamalesh M, Subramanian U, Sawada S, Eckert G, Temkit M, Tierney W. Decreased survival in diabetic patients with heart failure due to systolic dysfunction. Eur J Heart Fail. 2006;8(4):404–408
  118. Tory K, Horvath E, Suveges Z, et al. Effect of propranolol on heart rate variability in patients with end-stage renal disease: a double-blind, placebo-controlled, randomized crossover pilot trial. Clin Nephrol. 2004;61(5):316–323
  119. Bristow MR. What type of beta-blocker should be used to treat chronic heart failure?. Circulation. 2000;102(5):484–486
  120. Orth SR, Amann K, Strojek K, Ritz E. Sympathetic overactivity and arterial hypertension in renal failure. Nephrol Dial Transplant. 2001;16(suppl 1):S67–S69
  121. Paoletti E, Specchia C, Di Maio G, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant. 2004;19(7):1829–1834
  122. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24(3):495–499
  123. Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med. 1993;329(9):611–615
  124. Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ. Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med. 1999;16(10):813–819
  125. Prakash S, Garg AX, Heidenheim AP, House AA. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. Nephrol Dial Transplant. 2004;19(10):2553–2558
  126. Rubinstein S, Haimov M, Ross MJ. Midodrine-induced vascular ischemia in a hemodialysis patient: a case report and literature review. Ren Fail. 2008;30(8):808–812
  127. Yalcin AU, Kudaiberdieva G, Sahin G, et al. Effect of sertraline hydrochloride on cardiac autonomic dysfunction in patients with hemodialysis-induced hypotension. Nephron Physiol. 2003;93(1):P21–P28
  128. Agarwal A, Anand IS, Sakhuja V, Chugh KS. Effect of dialysis and renal transplantation on autonomic dysfunction in chronic renal failure. Kidney Int. 1991;40(3):489–495
  129. Allon M, Rodriguez M, Llach F. Insulin in the acute renal adaptation to dietary phosphate restriction in the rat. Kidney Int. 1990;37(1):14–20
  130. Rubinger D, Revis N, Pollak A, Luria MH, Sapoznikov D. Predictors of haemodynamic instability and heart rate variability during haemodialysis. Nephrol Dial Transplant. 2004;19(8):2053–2060
  131. Tong YQ, Hou HM. Alteration of heart rate variability parameters in nondiabetic hemodialysis patients. Am J Nephrol. 2007;27(1):63–69
  132. Dursun B, Demircioglu F, Varan HI, et al. Effects of different dialysis modalities on cardiac autonomic dysfunctions in end-stage renal disease patients: one year prospective study. Ren Fail. 2004;26(1):35–38
  133. Rubinger D, Backenroth R, Pollak A, Sapoznikov D. Blood pressure and heart rate variability in patients on conventional or sodium-profiling hemodialysis. Ren Fail. 2008;30(3):277–286
  134. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37(4):589–596
  135. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326(19):1250–1256
  136. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42(2):135–144
  137. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109–118
  138. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006;7(5):373–385
  139. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411–1420
  140. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831–1836
  141. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110(3):628–638
  142. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115(3):254–263
  143. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6(4):253–260
  144. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50(6):1842–1846
  145. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118(3):289–305
  146. Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr Opin Neurol. 2009;22(5):467–474
  147. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8(suppl 2):S50–S62
  148. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;3:CD007076
  149. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277–283
  150. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25(1):81–104
  151. Wong MO, Eldon MA, Keane WF, et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol. 1995;35(6):622–626
  152. Zhang C, Glenn DG, Bell WL, O'Donovan CA. Gabapentin-induced myoclonus in end-stage renal disease. Epilepsia. 2005;46(1):156–158
  153. Hung TY, Seow VK, Chong CF, Wang TL, Chen CC. Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia. Emerg Med J. 2008;25(3):178–179
  154. Jones H, Aguila E, Farber HW. Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis [letter]. Ann Intern Med. 2002;137(1):74
  155. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000;20(6):449–458
  156. Jann MW, Slade JH. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy. 2007;27(11):1571–1587
  157. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005;3:CD001133
  158. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain. 1999;83(1):85–90
  159. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105(1-2):71–78
  160. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352(13):1324–1334
  161. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374(9697):1252–1261
  162. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy (Capsaicin Study Group). Diabetes Care. 1992;15(2):159–165
  163. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473–1478
  164. Klassen A, Di Iorio B, Guastaferro P, Bahner U, Heidland A, De Santo N. High-tone external muscle stimulation in end-stage renal disease: effects on symptomatic diabetic and uremic peripheral neuropathy. J Ren Nutr. 2008;18(1):46–51

 Originally published online as doi: 10.1053/j.ajkd.2009.10.050 on December 31, 2009.

PII: S0272-6386(09)01448-6

doi: 10.1053/j.ajkd.2009.10.050

American Journal of Kidney Diseases
Volume 55, Issue 2 , Pages 365-385 , February 2010

Article Tools

* Image Usage & Resolution